

Product Data Sheet

PF-06426779

Cat. No.: HY-123854 CAS No.: 1817628-40-2

Molecular Formula: $C_{17}H_{18}FN_3O_4$ Molecular Weight: 347.34

Target: IRAK

Pathway: Immunology/Inflammation

Storage: Powder -20° C 3 years 4° C 2 years

In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (287.90 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8790 mL	14.3951 mL	28.7902 mL
	5 mM	0.5758 mL	2.8790 mL	5.7580 mL
	10 mM	0.2879 mL	1.4395 mL	2.8790 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: 2.08 mg/mL (5.99 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution

BIOLOGICAL ACTIVITY

PF-06426779 is a potent and selective inhibitor of interleukin №1 receptor associated kinase 4 (IRAK4), with an IC₅₀ of 0.3 nM

[1].

IC₅₀ & Target IRAK4

0.3 nM (IC₅₀)

In Vitro PF-06426779 inhibits IRAK4, with an IC₅₀ of 12.7 nM in the peripheral blood mononuclear cells (PBMCs) assay^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Lee KL, et, al. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017 Jul 13; 60(13): 5521-5542.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com